China Medical System Holdings Limited (2M7C.F)

China Medical System Holdings Limited (2M7C.F) — VMCI valuation read

Headline read on 2M7C.F: VMCI of 60/100 versus a Healthcare sector median of 50. The 10-point above-median position is what makes China Medical System Holdings Limited a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 2M7C.F: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 2M7C.F: value (2M7C.F trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.1x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

2M7C.F rose 2.4% over the trailing 7 days, with a -15.0% read on a 30-day basis.